BioPharmSignal logoBioPharmSignal

Biotech News

Enlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal

Enlivex Therapeutics (ENLV)Enlivex TherapeuticsCompany update

Nes-Ziona, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced receipt of a delisting notification dated October 26, 2026 (the "Delisting Notice") from the Listing Qualifications Department of The...

Related news

ENLVEnlivex Therapeutics2026-10-22 22:16 EST

Enlivex Announces 1-for-16 Reverse Share Split to be Effective October 27, 2026

ENLVEnlivex Therapeutics2026-09-22 13:00 EST

Enlivex Announces Termination of Previously-Announced Financing Payable in RAIN Tokens

GNTAGenenta Science2026-10-21 20:01 EST

Genenta Science Announces Receipt of Nasdaq Minimum Bid Price Deficiency Notification

CADLCandel Therapeutics2026-11-05 21:06 EST

Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CADLCandel Therapeutics2026-11-02 21:05 EST

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IMMPImmutep Limited2026-10-13 12:00 EST

Immutep Regains Compliance with Nasdaq Minimum Bid Price Requirement

View all latest news

Enlivex Therapeutics

Enlivex Therapeutics is an immunotherapy company focused on macrophage reprogramming and inflammation-related disease. Its story is centered on harnessing innate immunity to address hard-to-treat conditions.

Recent company news

ENLVEnlivex Therapeutics2026-11-02 14:00 EST

Enlivex Announces Favorable 12-Month Topline Data from Phase I/IIa Allocetra Trial, Demonstrating Durable Treatment Response

ENLVEnlivex Therapeutics2026-10-28 13:00 EST

Enlivex Announces Randomization of 135 Patients in Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

ENLVEnlivex Therapeutics2026-10-28 13:00 EST

Enlivex Announces Randomization of 135 Patients in Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

ENLVEnlivex Therapeutics2026-10-27 13:00 EST

Enlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal

ENLVEnlivex Therapeutics2026-10-27 13:00 EST

Enlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal

Stock data

Close
1.27 USD
Market cap
204.87M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States